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Alzheimer’s disease (AD) is the most common type of dementia. In connection with the global trend of prolonging human life
and the increasing number of elderly in the population, the AD becomes one of the most serious health and socioeconomic
problems of the present. Tau protein promotes assembly and stabilizes microtubules, which contributes to the proper function
of neuron. Alterations in the amount or the structure of tau protein can aﬀect its role as a stabilizer of microtubules as well as
some of the processes in which it is implicated. The molecular mechanisms governing tau aggregation are mainly represented by
several posttranslational modiﬁcations that alter its structure and conformational state. Hence, abnormal phosphorylation and
truncation of tau protein have gained attention as key mechanisms that become tau protein in a pathological entity. Evidences
about the clinicopathological signiﬁcance of phosphorylated and truncated tau have been documented during the progression
of AD as well as their capacity to exert cytotoxicity when expressed in cell and animal models. This paper describes the normal
structure and function of tau protein and its major alterations during its pathological aggregation in AD.
1.Introduction
Alzheimer’s disease (AD) is the most common type of
dementia characterized by memory impairment and alter-
ation of diverse cognitive abilities. In association with
the global trend of prolonging human life and increasing
number of elderly in the human population, AD becomes
one of the most important health and socioeconomic
problems of the present. AD and related tauopathies are
histopathologically characterized by slow and progressive
neurodegeneration, which is associated mostly with intra-
cellular accumulation of tau protein leading to the so-
called neuroﬁbrillary tangles (NFTs) and other inclusions
containing modiﬁed tau [1]. Tau protein was discovered
in the mid-1970s of the 20th century by studying factors
necessary for microtubule formation. Tau protein promotes
tubulin assembly into microtubules, one of the major
components of the neuronal cytoskeleton that deﬁnes the
normal morphology and provides structural support to
the neurons [2]. Tubulin binding of tau is regulated by
its phosphorylation state, which is regulated normally by
coordinated action of kinases and phosphatases on tau
molecule [3, 4]. In pathological conditions, such as the
case in AD, not only does abnormal phosphorylation of
tau protein decrease its tubulin binding capacity leading
to microtubule disorganization, but also this protein self-
polymerizes and aggregates in the form of NFTs [5, 6].
2. The Tau Gene
The human tau gene is located over 100 kb on the long arm
of chromosome 17 at band position 17q21 and contains 162 International Journal of Alzheimer’s Disease
exons. Exon 1 is part of the promoter and is transcribed
but not translated. Exons 1, 4, 5, 7, 9, 11, 12, and 13 are
constitutiveexons.Exons2,3,and10arealternativelyspliced
and manifesting in the adult brain. Exon 2 can appear alone,
but exon 3 never appears independently of exon 2 [7]. In
the central nervous system, alternative splicing of exons 2,
3, and 10 results in the appearance of six tau isoforms that
are diﬀerentially expressed during development of the brain
[7].
3. Structure and Function of Tau Protein
Tau protein belongs to a group of proteins referred to as
Microtubule-Associated Proteins (MAPs), that in common
are heat resistant and limited aﬀected by acid treatment
without loss their function [8]. This property observed in
tau is due to a very low content of secondary structure.
In fact, a number of biophysical studies revealed that tau
is a prototypical “natively unfolded” protein [9–11]. Since
disordered proteins tend to be highly ﬂexible and have
variable conformations, they have not been amenable for
structure analysis by crystallography so far. Thus nuclear
magnetic resonance spectroscopy is the only plausible
method that allows a description of their conformations and
dynamics with high resolution [12]. Now it is possible to
obtain the complete backbone assignment of 441-residue
tau (the longest tau isoform found in the human central
nervoussystem;Figure 1).Thismakesitpossibletoprobethe
structureanddynamicsofthefull-lengthsolubleproteinand
determine the residues involved in the interaction between
tau and microtubules at single residue resolution [13].
Six isoforms of tau protein diﬀer according to the
contents of three (3R) or four (4R) tubulin binding domains
(repeats, R) of 31 or 32 amino acids in the C-terminal
part of tau protein and one (1N), two (2N), or no inserts
of 29 amino acids each in the N-terminal portion of the
molecule. These isoforms, which vary in size from 352
to 441 amino acid residues, are related to the presence
or absence of sequences encoded by exons 2, 3, or 10.
Inclusion of the imperfect repeat region encoding exon 10
leads to the expression of tau containing four microtubule-
binding repeats (MTBRs) (4R tau: 0N4R, 1N4R, 2N4R),
while exclusion of exon 10 results in splicing products
expressing tau with three MTBRs (3R tau: 0N3R, 1N3R,
2N3R) [7, 14]. These six isoforms are also referred to as τ3L,
τ3S, τ3, τ4L, τ4S, and τ4[ 15]. Primary sequence analysis
demonstrates that tau consists of a half-N-terminal acidic
portion followed by a proline-rich region and the C-terminal
tail, which is the basic part of the protein. The polypeptide
sequences encoded by exons 2 and 3 add acidity to tau,
whereas exon 10 encodes a positively charged sequence that
contributes to the basic character of tau protein. On the
other hand, the N-terminal region has an isoelectric point
(pI) of 3.8 followed by the proline-rich domain, which has a
pI of 11.4. The C-terminal region is also positively charged
with a pI of 10.8. In other words, tau protein is rather a
dipole with two domains of opposite charge, which can be
modulated by posttranslational modiﬁcations [16]. Because
each of these isoforms has speciﬁc physiological roles, they
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Figure 1: Amino acid sequence of the longest tau isoform
(441 amino acids). N1 and N2: the polypeptide sequences
encoded by exons 2 and 3; P1 and P2: proline-rich regions;
R1–R4: microtubule-binding domains encoded by exons 9–
12; 275VQIINK280 and 306VQIVYK311: sequences with β-structure
(modiﬁed by [13]).
are diﬀerentially expressed during the development of the
brain. For instance, only one tau isoform, characterized by
3R and no N-terminal inserts, is present during fetal stages,
while the isoforms with one or two N-terminal inserts and 3-
or 4R are expressed during adulthood [7].
Tau protein is present in a greater extent in axons from
neurons, but it also occurs in the oligodendrocytes. Another
microtubule-binding protein referred to as MAP2 is located
in the somatodendritic compartment of neurons, whereas
MAP4 is much ubiquitous [17].
3.1. The Projection Domain and Its Interaction with Other
Molecules. The two 29-amino-acid sequences encoded by
exons 2 and 3 give diﬀerent lengths to the N-terminal part
of tau protein. The N-terminal part is referred to as the
projection domain since it projects from the microtubule
surfacewhereitmayinteractwithothercytoskeletalelements
and the neuronal plasma membrane. In fact, the projection
domains of tau protein determine spacing between micro-
tubules in the axon and may increase the axonal diameter
[7, 18]. Peripheral neurons often project a very long axon
with a large diameter. This type of neurons contains an
additional N-terminal tau sequence encoded by exon 4A and
sogeneratesaspeciﬁctauisoformcalled“bigtau”[7,18–20].
As to the interactions with other cytoskeletal components,
tau protein binds to spectrin and actin ﬁlaments, which
may allow tau-stabilized microtubules to interconnect with
neuroﬁlaments that restrict the ﬂexibility of the microtubule
lattices. Another molecule that interacts with tau protein
is a peptidyl-prolyl cis/trans isomerase Pin 1. It isomerizes
only phosphoserine/threonine-proline motifs and binds toInternational Journal of Alzheimer’s Disease 3
the tau protein after its phosphorylation on Thr231 residue.
Isomerization induces conformational changes that make
tau accessible for Protein Phosphatase (PP) 2A, which in
turn leads to tau dephosphorylation. Protein Pin 1 regulates
functions of tau protein and APP and is important for
protection against the degeneration that occurs during the
ageing process. Activity of Pin 1 is decreased by oxidation in
AD [21]. Moreover, tau protein through its N-terminal pro-
jection domain may interact with intracellular membranous
elements such as the mitochondria [22] and the neuronal
plasma membrane [23]. In the cytosol of neurons the pools
of tau protein in either phosphorylated or dephosphorylated
forms are maintained in equilibrium by coordinated actions
of kinases and phosphatases, respectively. Several studies in
cell lines revealed that tau protein bound to the plasma
membrane is dephosphorylated [24, 25]. Tau protein binds
through its proline-rich region to the Src-homology 3 (SH3)
domains of several proteins, including Fyn, a tyrosine kinase
from the Src-family. The association of tau and Fyn depends
on the phosphorylation state of tau, because insoluble PHF-
tau isolated from AD brain does not bind to the Fyn SH3
domain [26]. Recently, Fyn has been demonstrated to play
ar o l ei np r o t e i nt r a ﬃcking [27]. For example, Fyn can
increase the surface expression of the amyloid precursor
protein (APP) through tyrosine phosphorylation [28]. The
traﬃcking of tau protein to the plasma membrane is a
bidirectional process, because increased tau phosphorylation
inducedbyPP2Ainhibition signiﬁcantlyreducesthepropor-
tion of membrane-associated tau. The active relocalization
of tau in response to changes in phosphorylation suggests
a possible role of this protein in intracellular signaling
pathways [29, 30]. It was recently shown that tau binds
to the Fyn in dendritic spines, and this interaction regu-
lates N-methyl-D-aspartic acid (NMDA) receptor signaling
[31]. Pathological tau may participate in the localization
of Fyn kinase to the postsynaptic compartment, where it
phosphorylates NMDAR subunits, causing increased inward
Ca2+ conductance and leading to excitotoxicity [32]. In
vivo, tau has been demonstrated to interact directly with
ionotropicglutamatereceptors[33].Inoligodendrocytes,the
association of tau with Fyn regulates the outgrowth of cyto-
plasmic process [34]. Impaired interaction of Fyn kinase and
hyperphosphorylated tau protein leads to hypomyelination
andevolvingdemyelinationofaxons[34].Alltheseevidences
indicate that the phosphorylated state of tau protein not only
aﬀects microtubule stability but also produces alterations on
neuronal plasticity.
3.2. The Domain Associated with the Microtubules. Tau
protein binds microtubules through some repeated domains
(R1–R4) (encoded by exons 9–12) located at the C-terminus
of the molecule (Figure 2)[ 35]. Each repeat consists of
stretches of a highly conserved 18 residues that are imper-
fectly repeated three times in the fetal tau protein and
four times in the adult speciﬁc form [35]. The repeats
are separated from each other by 13- or 14-residue spacer
regions. The main function of tau, aforementioned as a
promoter of tubulin polymerization, depends mostly on
the MTBR [35, 36]. It has been reported that in vitro tau
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Figure 2: Normal function of tau protein. Tau protein stabilizes
microtubules through four tubulin binding domains (blue boxes)
in case of the longest isoform. Binding of tau protein to the
microtubules is maintained in equilibrium by coordinated actions
of kinases and phosphatases. The phosphorylation of tau (pink
balls) regulates its activity to bind to microtubules and can aﬀect
axonal transport. Tau protein may inhibit the plus-end-directed
transport of vesicles along microtubules by kinesin.
protein increases the rate of microtubule polymerization
and concomitantly inhibits its rate of depolymerization [37].
The 18-amino-acid repeats bind to microtubules through
a ﬂexible array of distributed weak sites. The adult form
of tau promotes assembly of microtubules more actively
than fetal forms [14, 38]. Interestingly, the most potent
part that induces microtubule polymerization is the inter-
region between repeats 1 and 2 (R1-R2 interregion) and
more speciﬁcally the peptide 275KVQIINKK280 within this
sequence [7, 39]. This R1-R2 interregion is unique to 4R
tau, adult speciﬁc, and responsible for the diﬀerence in the
binding aﬃnities between 3R and 4R tau [7, 35]. Recent
evidence supports a role for the MTBR in the modulation
of the phosphorylation state of tau protein. A direct and
competitive binding has been demonstrated between this
region (residues 224–236 according to the numbering of the
longest isoform) and the microtubule on one hand and the
same region with the PP2A on the other hand [40]. As a
consequence, microtubules could inhibit PP2A activity by
competing for binding to tau at the MTBR.
Microtubules contribute to diverse cellular processes
such as cell morphogenesis, cell division, and intracellular
traﬃcking [41, 42]. In cells, microtubules can change their
lengths via dynamic instability [43]. They can serve as
tracks for organelle transport mediated by microtubule-
dependent motor proteins such as the plus-end-directed
motor kinesin and its relatives, or the minus-end-directed
motor dynein [44, 45]. These motors can transport their
cargoes, for example, mitochondria [46, 47], lysosomes [48],
peroxisomes[49],andendocytotic orexocytotic vesicles[50]
towards the cell periphery or back towards the microtubule
organizing center (MTOC), respectively. It has been shown
that tau protein aﬀects axonal transport [17, 51, 52]. Tau
protein alters intracellular traﬃc due to its tight binding
to microtubules and probably detaches the cargoes from
kinesin. Nevertheless, tau protein has no inﬂuence on speed4 International Journal of Alzheimer’s Disease
of kinesin with cargoes [52]. This implies that the phospho-
rylation of tau should play an important role because this
modiﬁcation regulates tau’s aﬃnity to microtubules.
4.TauPathology
In AD, the normal role of tau protein is ineﬀective to keep
thecytoskeletonwellorganizedintheaxonalprocessbecause
this protein loses its capacity to bind to microtubules. This
abnormal behavior is promoted by conformational changes
and misfoldings in the normal structure of tau [53–55] that
leads to its aberrant aggregation into ﬁbrillary structures
inside the neurons of demented individuals [56–58]. Thus,
most of the altered pools of tau protein in the disease are
redistributed and aggregated in both the somatodendritic
compartment and isolated processes of aﬀected neurons.
Alterations in the amount or the structure of tau protein
can aﬀect stabilization of microtubules and other processes
related to this protein [59, 60].
For instance, overexpression or mislocalization that
increase intracellular concentration of tau may inhibit the
plus-end-directed transport of vesicles along microtubules
by kinesin so that the minus-end-directed transport by
dyneinbecomesmoredominant[17].Inhibitionoftransport
to the plus-end of microtubule slows down exocytosis and
aﬀects the distribution of mitochondria which become clus-
tered near to the MTOC. The absence of mitochondria and
endoplasmic reticulum in the peripheral regions of the axons
could produce a decrease in glucose and lipid metabolism
and ATP synthesis and loss of Ca2+ homeostasis [61] that
leads to a distal degeneration process referred to as “dying
back” of axons [62]. Moreover, phosphorylated tau protein
has aﬃnity to the kinesin and therefore is transported to the
distal sites of neuropil. This may account for the observation
that tangle pathology in AD appears to initiate distally and
then spreads in a retrograde fashion to the perikaryon. This
process may be a mechanism to protect the stability of
the microtubules by transporting hyperphosphorylated tau
more rapidly to other cellular locations where tau can form
aggregates [51].
The mechanisms by which tau protein becomes a
nonfunctional entity are in debate. Abnormal posttrans-
lational modiﬁcations are proposed to be the main cause
of this failure [63, 64]. In this regard, abnormal phos-
phorylation (hyperphosphorylation), acetylation, glycation,
ubiquitination, nitration, proteolytic cleavage (truncation),
conformational changes, and some other modiﬁcations [53,
65–73] have been proposed to cause the loss of normal
function and the gain of pathological features of tau protein.
In the upcoming sections we will focus our interest to
describe evidence supporting abnormal phosphorylation,
acetylation, and truncation of tau as major changes during
the pathological processing of tau protein in AD.
4.1. The Hyperphosphorylation of Tau Protein. The phospho-
rylation of tau regulates its activity to bind to microtubules
and stimulate their assembly as previously outlined. A
normal level of phosphorylation is required for the optimal
function of tau, whereas the hyperphosphorylated state
makes tau to lose its biological activity. Regarding the
potential propensity of tau protein to be phosphorylated,
it was reported that the longest variant of tau protein (441
amino acid) holds about 80 potential serine or threonine
phosphorylation sites [7]. Most of these potential sites are
locatedatthevicinityoftheMTBRintheproline-richregion
and in the C-terminal extreme of the molecule of tau protein
[16,74]withtheexceptionofSer262,Ser 293,Ser 324,andSer 356
(motif KXGS) in R1, R2, R3, and R4 domains [75, 76].
In the disease the abnormal phosphorylation of tau could
be, but not mutually exclusive, the result of upregulation
of tau kinase(s) or downregulation of tau phosphatase(s)
[62,74].Anumberoftheseenzymeshavebeenevaluatedand
those kinases that are believed to play the most important
role in phosphorylation of tau in the brain include GSK-
3β, cyclin-dependent kinase 5 (cdk5), cAMP-dependent
protein kinase (PKA), and calcium/calmodulin-dependent
kinase II (CaMK-II) [77]. GSK-3β m a yp l a ym a j o rr o l ei n
regulating tau phosphorylation in both physiological and
pathological conditions. GSK-3β can phosphorylate tau on
Ser199,T h r 231,S e r 396,S e r 400,S e r 404,a n dS e r 413in vivo and
in vitro (numbered according to the longest tau isoform),
residues that are mostly phosphorylated in PHF-tau [78].
Aforementioned phosphorylation at Thr231 causes a local
conformational change that allows the access of GSK-3β or
other kinases to further phosphorylate tau. On the other
hand, a complementary and opposite eﬀect is for PP1, PP2A,
PP2B, and PP2C that can dephosphorylate tau protein in
vitro [79]. The activity of PP2A has been found to be
r e d u c e di ns e l e c t e da r e a so ft h eb r a i no fA Dp a t i e n t s[ 4].
Overalltauphosphoproteinisatleastthree-tofourfoldmore
hyperphosphorylatedinthebrainofADpatientsthanthatin
the brain of aged nondemented individuals [80].
At cellular level, abnormal phosphorylation of tau intro-
duces alterations in several processes which are directly
regulated by the suitable organization of the microtubule
network. In a normal mature neuron, tubulin is present in
over tenfold excess of tau, and thus practically all tau protein
is microtubule bounded in the cell [81, 82]. In neurons
aﬀected in AD, abnormally phosphorylated cytosolic tau
(AD P-tau) neither binds to tubulin nor promotes micro-
tubule assembly [83–85]. Instead, this protein inhibits the
assembly and disrupts the microtubule organization [83].
Moreover, it was reported that abnormally phosphorylated
tau protein disengages normal tau from microtubules into
the cytosolic phase [83], as much as 40% of the abnormally
hyperphosphorylated tau in the brain of AD patients is
presentinthecytosolandnotpolymerizedintopairedhelical
ﬁlaments (PHFs) or forming NFTs [80]. The AD P-tau also
removes the other two major neuronal MAPs, MAP1 and
MAP2, from microtubule lattice [86]. This toxic feature
of the AD P-tau appears to be solely due to its abnormal
phosphorylation state because dephosphorylation of AD P-
tau rescues this protein to perform its normal tasks [84].
Byusingaphosphorylation-dependentmonoclonalanti-
bodies against tau and mass spectrometry, it was reported
that at least 39 phosphorylated sites in the tau molecule are
associated with native PHF isolated from the brain of AD
patients [87].International Journal of Alzheimer’s Disease 5
As to the in situ aggregation of hyperphosphorylated
tau, a bunch of evidence has been generated over the years
to identify abnormally phosphorylated tau as the major
component of distinct neuropathological hallmarks that
deﬁnes AD [6, 15, 65, 88–90]. Hyperphosphorylated tau
has been observed as the major component of PHFs and
straight ﬁlaments (SFs), NFTs, neuropil threads (NTs), and
plaque-associated dystrophic neurites in the brain of AD
cases [81, 91]. The density of NFTs distributed along the
hippocampus, entorhinal cortex, and neocortex has been
correlated with the degree of dementia in this disorder
[92]. Moreover, the earliest accumulation of tau in the
hippocampus of AD patients, prior to the formation of
NFTs, has been viewed as a diﬀuse granular material
immunoreactive to phosphorylation-dependent tau anti-
bodies [93–95]. However, in the abnormal formation of
PHFs, tau molecules may follow diﬀerent alterations from
which abnormal phosphorylation (although this may not be
essential)causesmisfoldingandconformationalchangesthat
strength its abnormal aggregation [79, 96].
Recent studies demonstrated that hyperphosphorylation
oftauoccursbeforeitscleavage[97,98]andthattaucleavage
takes place before NFT formation [99]. In an in vitro model
of ethanol-induced neuronal apoptosis, hyperphosphoryla-
tion of tau occurs before tau cleavage [98, 100]. Altogether,
these results may indicate that abnormal phosphorylation is
a key event that triggers the pathological aggregation of tau
in AD.
4.2. The Acetylation of Tau Protein. The mechanism leading
normal soluble tau to become hyperphosphorylated and dis-
engaged from microtubules to form tau inclusions remains
unknown and posttranslational modiﬁcations other than
phosphorylation could regulate tau function and aggrega-
tion. Notably, reversible lysine acetylation has emerged as
a potential regulatory modiﬁcation implicated in AD and
other neurodegenerative disorders. Recent studies demon-
strate tau acetylation as a posttranslational modiﬁcation
that may regulate normal tau function [73, 101, 102].
Since acetylation neutralizes charges in the microtubule-
binding domain, aberrant acetylation might interfere with
thebindingoftautomicrotubule,leadingtotaudysfunction,
and suggests a role in pathological tau aggregation in
AD and related tauopathies [73]. Increased tau acetylation
on Lys280 could impair tau interactions with microtubules
and provide increased pools of cytosolic tau available for
pathologicalPHFaggregation[39,101].Consistentwiththis,
Lys280, located in the interrepeat region (275VQIINKK280),
was identiﬁed previously as one of three lysine residues
most critical in modulating tau-microtubule interactions
[39]. Acetylation of tau aggregates was associated with
hyperphosphorylated, ThS-positive tau inclusions in both
Tg mouse models and human tauopathies [101]. This
implies that negative regulation of tau function could
occur via phosphorylation and acetylation events alone or
in combination. The molecule of tau protein contains a
lot of phosphorylation sites, as mentioned previously, and
most of them occur in regions ﬂanking the microtubule-
binding repeat [74], in which Lys280 is located. Thus, tau
hyperphosphorylation may render this residue available
for subsequent acetylation, which would further impair
microtubule binding and/or promote tau aggregation as well
asfurtherdrivepathologicalalterationsoftau.Althoughpro-
tein acetylation has been extensively studied in the context of
histonesandgenetranscription,proteomicsapproacheshave
identiﬁed acetylated proteins in the cytoplasm and other
organelles [103]. Recent study suggests that acetylation of
Lys280 maybeanintermediatestepintangleformation[102].
Acetylated Lys280 was mostly associated with intracellular
neuroﬁbrillary tangles compared to pretangles or extracel-
lular ghost tangles throughout all Braak stages [73, 102].
Acetylated Lys280 also colocalizes with N- and C-terminal
speciﬁc antitau epitopes. This indicates that it is present in
neuroﬁbrillary tangles prior to subsequent tau truncation
[102].
Enzymesthataddanacetylgrouptotheproteinarecalled
histone acetyltransferase (HAT) or lysine acetyltransferase.
OffourmajorclassesofHATs,p300/CBP(proteinof300kDa
and CREB-binding protein) and pCAF (p300-associated and
CBP-associated factor) are exclusively present in metazoans
[104].Enzymesthatremoveanacetylgroupfromtheprotein
are called histone deacetylase (HDAC) or lysine deacetylase.
There are three classes of HDACs. The activities of HDACs in
classes I and II (HADC1–11) depend on zinc as a cofactor;
the activities of class III HDACs (sirtuins) depend on the
relative levels of NAD+ and NADH [105, 106]. Of the seven
members of mammalian sirtuins (SIRT1–7), SIRT1 is the
most studied and is strongly implicated in aging-related
diseases, including AD [107]. SIRT1 levels are reduced in AD
brains,andthereductioncorrelateswiththeaccumulationof
hyperphosphorylated tau aggregates [108]. SIRT1 was found
to reduce Aβ generation by activating transcription of a
gene encoding α-secretase [109]. SIRT1 deﬁciency could also
exacerbate the accumulation of Aβ, which could increase tau
acetylation and tau phosphorylation even further. Since a
decrease in SIRT1 activity can clearly have deleterious eﬀects
on neuron health, therapeutic strategies aiming at increasing
sirtuins activity in AD brain warrant further research.
4.3. The Aggregation of Tau Protein In Vitro. The molecule
of tau has long stretches of positively and negatively charged
regions that are not conducive for intermolecular hydropho-
bic association [81, 110]. The β-structure in monomeric
tau is concentrated only in R2 (exon 10) and R3 (exon
11), which can self-assemble by their own into ﬁlaments
[111] and coassemble with heparin as an artiﬁcial inducer
[112]. Evidence in vitro has revealed that self-aggregation
of tau into ﬁlaments is inhibited by the presence of intact
N- and C-termini, which lie down over the MTBR and
avoid the interaction between these sticky domains [15].
Abnormal phosphorylation of the N-terminal and the C-
terminal ﬂanking regions may induce a relaxed structural
conformation in the tau molecule that unclip both extremes
from the MTBR region. This situation allows the self-
interaction between these sticky domains in the formation
of PHF/SF (Figure 3)[ 15].
Some other modiﬁcations such as deamidation could
facilitate polymerization of tau protein. Curiously, several6 International Journal of Alzheimer’s Disease
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Figure 3: Phosphorylation of tau protein. Tau self-assembles mainly through the microtubule binding domains/repeat R3 in 3R tau proteins
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regions to the repeats are inhibitory. Hyperphosphorylation of tau neutralizes these basic inhibitory domains, enabling tau-tau interaction
(phosphorylation sites indicated by violet Ps) (modiﬁed by [15]).
years later, it was shown that deamidation occurs in tau
obtained from PHF [113]. Because a high concentration of
tau protein is needed to polymerize [114], some suggest that
other compounds, acting as cofactors, could be necessary
to facilitate the self-assembly of tau protein [115–117].
Regardless of the phosphorylation state of tau protein, it
was found that sulfoglycosaminoglycans (sGAGs), a class of
polyanionic molecules, facilitate the polymerization of tau in
vitro [115, 116]. Moreover, these sGAGs were found along
with tau in NFTs, when the tau-neuroﬁbrillary pathology
was analyzed in the brain of AD cases [115, 116]. In vitro,
tau polymerization paradigms also have utilized arachidonic
acid as a polyanionic inducer [118], resulting in increased
rates of ﬁlament formation. Other native polyanions such
as the glutamic acid-rich region present at the C-terminal
region of tubulin can also facilitate the aggregation of tau
protein. This aggregation requires the presence of the third
tubulinbindingmotifofthetaumolecule[115].Oxidationis
anotherprocessthatfacilitatestheaggregationoftauprotein.
Because3Rtaumoleculescontainonlyonecystein,oxidation
of cystein produces disulﬁde cross-linking and thus self-
assembly of tau protein [119]. It does not occur in 4R tau
moleculeswithtwocysteins,whichmayformintramolecular
disulﬁde bonds [119].
Despite in vitro formed tau polymers have been demon-
strated by spectroscopy, laser scattering, and electron
microscopy [120–123], recent ﬁndings demonstrate that
preﬁbrillar tau oligomers can be formed in vitro by
light-induced cross-linking of tau with benzophenone-4-
maleimide (B4M) [123]. These oligomers of tau were also
observed in situ at the early stages of AD, when a monoclonal
and speciﬁc antibody to these oligomeric entities of tau was
assessed in the brain of AD cases [123]. Oligomeric species
of tau protein are reported to have increased toxicity over
soluble and high-ordered ﬁbrillary aggregates such as NFTs
[124–126]. In transgenic mice that overexpress tau, most
of the observed cognitive alterations emerged at stages of
profound occurrence of multimeric aggregates of tau and
prior to the formation of NFTs [126].
4.4. The Truncation of Tau Protein. Proteolytic cleavage of
tau protein, as an alternative mechanism involving in
the abnormal aggregation of tau, was early proposed by
Whischik’s group at Cambridge University after extensive
biochemical analysis of the minimal structure of the PHFs
[69, 127, 128]. The minimal component of PHFs, referred
to as the PHF core, was mostly composed of a fragment
of tau only containing the region of the MTBR and ending
at the position Glu391. Until today, identiﬁcation of the
enzyme that produces this proteolytic cleavage is uncertain.
However, the presence of this truncation associated with
the neuroﬁbrillary pathology has been demonstrated in the
brain of AD patients [129, 130]. Furthermore, from in vitro
paradigms of polymerization, tau constructs lacking the
carboxy tail assembled much faster and to a greater extent
than full length tau [131]. Despite these early evidences,
attention was not focused for a while on the proteolysis of
tau, and its contribution to the disease was uncertain. New
ﬁndings show aberrant proteolysis in the brain of AD cases
associated with programmed cell death [132, 133]. Further
studies were dedicated to investigate the contribution of
apoptosisandassociatedcaspasesintotheneurodegenerative
process underlying AD. In this regard, apoptotic cells were
observed toproliferatein areasof thebrainthatwereaﬀected
by ﬁbrillary accumulation of tau protein and amyloid-β
deposits [134–136]. Concomitantly, increased expression of
several enzymes of the family of caspases was reported in the
brain of AD cases [99, 137, 138].International Journal of Alzheimer’s Disease 7
Caspases are cysteine proteases that cleave aspartic acid
residue in the canonical consensus sequence DXXD on the
carboxy side of molecule. These enzymes participate in
a proteolytic cascade leading to cell death via apoptosis.
The major killer caspase in neurons is caspase 3 [139].
Members of the caspase family play a critical role in Aβ-
induced neuronal apoptosis [140] and are activated in
apoptotic neurons in AD [141]. It was known that tau
protein contains several canonical sites for caspase cleavage
[142, 143], from which a susceptible residue at Asp421 was
reported to be cleaved in vitro by caspase 3 [72]. The cleavage
at Asp421 released a discrete peptide (Ser422-Leu441) that
is capable of forming an amphipathic α-helix [144]. Tau
protein truncated at Asp421 assembled more readily than the
full-length molecule [72, 144]. When a synthetic peptide
comprising the fragment after caspase cleavage was added
back to the tau molecule in a polymerization paradigm,
assembly of this protein was inhibited.
Inthedisease,theoccurrenceoftruncationoftauprotein
at Asp421 was corroborated in association with the neuroﬁb-
rillary pathology by using the monoclonal antibody Tau-C3,
which speciﬁcally recognizes this cleavage site generated by
caspase 3 activity [72, 145]. Interestingly, phosphorylation
of tau protein at residue Ser422 seemed to prevent the
proteolytic cleavage of tau at Asp421 [146]. After truncation
atAsp421 anothercleavageoftauproteinhasbeenreportedto
occur at Glu391. This state is recognized by antibody MN423,
which indicates the transitions to “late” tangles [56, 67, 145].
Another truncation in the N-terminus of tau protein has
been reported to occur at the residue Asp13, which in this
case is produced by caspase 6 activity [147]. Despite the in
vitrodemonstration that this truncation at the N-terminus is
important to favor tau aggregation, its pathological meaning
and occurrence in the brain of AD patients is still far from
proven.
The pathological eﬀect of C-terminus truncated tau
over the normal functioning of the cells has been assessed
in cultured cells and transgenic animal models. By using
neuronal and nonneuronal cells, overexpression of truncated
tau protein produces several alterations in the organiza-
tion and functioning of membranous organelles, such as
mitochondria and the endoplasmic reticulum. Even some
examples of cell death by apoptotic mechanisms also have
been reported [148–156]. In transgenics animals, truncated-
tau carrying rodents have developed alterations in cognitive
performance associated with neuronal death and abnormal
aggregation of cleaved tau [100, 157–162].
Finally, the abnormal role of truncation of tau protein
and its pathological signiﬁcance in AD has been demon-
strated by clinicopathological studies where the occurrence
of truncated tau associated with ﬁbrillary structures was
analyzed during the development of the dementia [130,
145, 163]. These studies corroborate the importance of the
truncated tau protein at both sites Asp421 and Glu391.A
positive correlation of these events with neuropathological
progression of the disease was described by H. Braak and
E. Braak [164] and a relationship to the clinical severity
of dementia was demonstrated [130, 163]. Moreover, the
presence of the Apolipoprotein-E (ε4) allelic variant was
found in cases with an increased density of NFTs composed
by the two variants of truncated tau [163].
In the hippocampus of AD patients, the maturation of
NFTs is reported to be unsynchronized. Therefore these
structures have diﬀerent stages of tau processing [163]. It
was reported that diﬀerent populations of NFTs in the same
hippocampal area were mutually exclusive when they were
composed of either Asp421-o rG l u 391-truncated tau with
no colocalization at any single point during the maturation
of the NFTs [163]. During the progression of the disease,
Asp421-truncation is an early event that precedes the second
truncation of the C-terminus at the Glu391, the later occur-
ring from intermediate to advanced stages of NFTs evolution
[163]. A recent report indicates that tau protein in NFTs
may be dually subjected to both apoptotic and proteosomal
proteolysis since strong ubiquitination was found in Asp421-
truncated tau associated with the neuroﬁbrillary pathology
in AD [165].
By combining of antibodies that map diﬀerent regions
of the molecule of tau, a continuous and speciﬁc pathway
of conformational changes and truncation of tau protein
has been proposed to occur during the maturation of
NFTs. These antibodies are, namely, conformational and
phosphorylation-dependentandrecognizingtruncationsites
[66, 67, 145].
These studies proposed that not only the number of
NFTs but also the state of proteolysis of the C-terminus
which is associated with conformational changes (structural
modiﬁcation along the tau molecule) deﬁnes the progression
of AD [166]. All these ﬁndings together may support the
relevance of truncation of tau protein as a pathogenic event
and reliable marker for both diagnosis and therapeutic
targeting in AD.
5. Conclusion
It is largely accepted that clinical manifestation of dementia
in AD is due to the neuronal loss occurring in those areas
of the brain associated with cognitive functions of the
patients. Fibrillary inclusions are reported to be responsible
for cell death. However, discrepancy has emerged from
studies demonstrating that cognitive impairment in animal
models occurs earlier than the initial formation of ﬁbrillary
structures. Extrapolation of these results to the real onset
of the disease in humans is still considered inaccurate
for some researchers. In this regard, a bunch of reports
analyzing the brain of AD patients come to an agreement
that ﬁbrillary aggregation of tau is the best correlator
with the onset and progression of dementia. It is mostly
accepted that abnormal posttranslational modiﬁcations, that
is, hyperphosphorylation, acetylation, glycation, nitration,
truncation, and others, are responsible for altered tau
structure in AD. Some of these events have been sequentially
staged during the formation of NFTs and the evolution of
the disease. Validation at clinicopathological levels with the
load of abnormally phosphorylated and truncated tau has
been demonstrated in populations of AD cases. Particularly
abnormal phosphorylation, acetylation, and truncation are8 International Journal of Alzheimer’s Disease
further supported as pathological events by in vitro experi-
ments demonstrating that these modiﬁcations increase ﬁb-
rillization of tau and induce cell toxicity in vitro. Transgenic
animals carrying these altered forms of tau protein also
develop cognitive alterations. We believe that resolving the
genesis of conformational changes of tau protein promoted
by these posttranslational modiﬁcations and its role in ﬁbril-
lization in disease are important achievements for assessing
the potential of tau-directed therapies. Moreover, accurate
determination of altered tau protein in the cerebrospinal
ﬂuid and other body ﬂuids may provide better expectation
to predict the onset and evolution of dementia.
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